ASB-7 Activators

ASB-7 Activators consist of a variety of chemical compounds that indirectly augment the functional activity of ASB-7, mainly through their interactions with the ubiquitin-proteasome system and autophagy pathways. Proteasome inhibitors like MG132, Bortezomib, Lactacystin, Epoxomicin, Velcade, Carfilzomib, MLN2238, Oprozomib, and Auranofin enhance ASB-7's role in protein ubiquitination by inhibiting the degradation of ubiquitinated proteins. These inhibitors lead to an accumulation of proteins that are substrates for ubiquitination, thereby increasing the demand for ASB-7's activity in tagging these proteins for degradation. By stabilizing these proteins, these compounds underscore the importance of ASB-7 in the ubiquitin-mediated proteasomal degradation pathway.

Additionally, autophagy inhibitors such as Chloroquine, 3-Methyladenine, and Concanamycin A also play a significant role in enhancing ASB-7 activity. They work by affecting lysosomal degradation pathways, leading to an increased reliance on the proteasomal system where ASB-7 functions. This shift in the cellular degradation mechanism enhances the need for ASB-7's ubiquitination activity.